

Barcelona, October 27th 2015

SIGNIFICANT EVENT

2015 GUIDANCE UPGRADED DUE TO OPERATIONAL OUTPERFORMANCE AND DUAKLIR® LAUNCH IN SOUTH KOREA

Almirall, S.A. (ALM.MC), as per section 82 of the Securities Market Act (Ley 24/1988 on 28 July, that regulates the Stock Market or *Mercado de Valores* in Spain) and other applicable provisions, hereby announces that:

We are pleased to inform you that a continued strong operational performance of the Almirall business means that the current EBIT guidance for 2015 will be exceeded. This is further boosted by the receipt of 20 million dollars from AstraZeneca related to the launch of Duaklir® in South Korea, as a bronchodilator to relieve symptoms of Chronic Obstructive Pulmonary Disease (COPD).

Consequently, we upgrade our EBIT Guidance 2015 from 100 million euros to 130 million euros and the Total Revenue from 720 - 750 to 740 - 770 million euros.

We note that the divestment of Constella®/Linzess® to Allergan, also announced today, has no impact on our EBIT Guidance.

Yours sincerely,

Pablo Divasson del Fraile
Investor Relations Department
inversores@almirall.com

